Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water LabelingRohit Loomba, Martin Decaris, Kelvin W Li, et al.
Hepatology International|February 22, 2019
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaAjit Sood, Ajay Duseja, Mayank Kabrawala, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Gastroenterology and Hepatology|March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patientsKeyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
Biomed Research International|May 9, 2017
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver DiseaseAhmed M Gharib, Ma Ai Thanda Han, Eric G Meissner, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Plos One|July 23, 2014
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearanceThomas H King, Charles B Kemmler, Zhimin Guo, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water LabelingRohit Loomba, Martin Decaris, Kelvin W Li, et al.
Hepatology International|February 22, 2019
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaAjit Sood, Ajay Duseja, Mayank Kabrawala, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Gastroenterology and Hepatology|March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patientsKeyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
Biomed Research International|May 9, 2017
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver DiseaseAhmed M Gharib, Ma Ai Thanda Han, Eric G Meissner, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Plos One|July 23, 2014
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearanceThomas H King, Charles B Kemmler, Zhimin Guo, et al.
Pageof 17